Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

BACKGROUND: In 2019, the World Health Organisation (WHO) recommended Dolutegravir (DTG) as the preferred first-line antiretroviral treatment (ART) for all persons with HIV. ART regimen switches may affect HIV treatment adherence. We sought to describe patient experiences switching from EFV to DTG-ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Twimukye, Adelline, Laker, Miriam, Odongpiny, Eva Agnes Laker, Ajok, Florence, Onen, Henry, Kalule, Ivan, Kajubi, Phoebe, Seden, Kay, Owarwo, Noela, Kiragga, Agnes, Armstrong-Hough, Mari, Katahoire, Anne, Mujugira, Andrew, Lamorde, Mohammed, Castelnuovo, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590364/
https://www.ncbi.nlm.nih.gov/pubmed/34774018
http://dx.doi.org/10.1186/s12879-021-06851-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590364/
https://www.ncbi.nlm.nih.gov/pubmed/34774018
http://dx.doi.org/10.1186/s12879-021-06851-9

Ejemplares similares